Literature DB >> 1581880

Three new cases of chromosome 3 rearrangement in bands q21 and q26 with abnormal thrombopoiesis bring further evidence to the existence of a 3q21q26 syndrome.

M Jotterand Bellomo1, V Parlier, D Mühlematter, J P Grob, P Beris.   

Abstract

Defects of 3q in bands q21 and q26 have been reported in more than 70 cases of acute nonlymphocytic leukemia (ANLL), myelodysplastic syndrome (MDS), and myeloproliferative disorder (MPD) in blast crisis. In this paper three additional patients are described: patient 1 with refractory anemia with excess of blasts in transformation (RAEB-T) and inv(3)(q21q26), patient 2 with RAEB-T and t(3;3)(q21;q26), and patient 3 with myelofibrosis with myeloid metaplasia (MMM) in blast crisis and inv(3)(q21q26). In addition to 3q rearrangements, monosomy 7 and del(7)(q22q36) were observed in patients 1 and 2, respectively. In the three patients, the most characteristic clinical features were elevated platelet counts, marked hyperplasia with dysplasia of the megakaryocytes, and poor prognosis. Although disturbance of thrombopoiesis was not systematically observed in all patients with t(3;3)(q21;q26), inv(3)(q21q26), and ins or dup(3)(q21----q26), study of the 77 cases reported and of the three cases presented here brings further evidence to the existence of a cytogenetic syndrome involving bands q21 and q26 simultaneously, which represents a subtype of ANLL, MDS, and MPD, characterized by normal or elevated platelet counts, hyperplasia with dysplasia of megakaryocytes, multilineage involvement, young median age of patients with MDS, preferential involvement of women in t(3;3), high incidence of chromosome 7 defects in MDS and ANLL, short duration of the MDS phase, no response to chemotherapy, short survival, and por prognosis.

Entities:  

Mesh:

Year:  1992        PMID: 1581880     DOI: 10.1016/0165-4608(92)90208-p

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  7 in total

1.  Loss of erythropoietin responsiveness in erythroid progenitors due to expression of the Evi-1 myeloid-transforming gene.

Authors:  B L Kreider; S H Orkin; J N Ihle
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

Review 2.  Molecular pathogenesis of MDS.

Authors:  Hisamaru Hirai
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

3.  Myeloid neoplasms associated with t(3;12)(q26.2;p13) are clinically aggressive, show myelodysplasia, and frequently harbor chromosome 7 abnormalities.

Authors:  Arash Ronaghy; Shimin Hu; Zhenya Tang; Wei Wang; Guilin Tang; Sanam Loghavi; Shaoying Li; Beenu Thakral; L Jeffrey Medeiros; Tariq Muzzafar
Journal:  Mod Pathol       Date:  2020-10-27       Impact factor: 7.842

4.  Mutant N-RAS induces erythroid lineage dysplasia in human CD34+ cells.

Authors:  R L Darley; T G Hoy; P Baines; R A Padua; A K Burnett
Journal:  J Exp Med       Date:  1997-04-07       Impact factor: 14.307

5.  Azacitidine as salvage therapy for acute myeloid leukemia in a severely ill patient.

Authors:  Harry Ross Powers; Moshe Bachar; Natasha Savage; Michael Toscano; Paul M Dainer
Journal:  Hematol Rep       Date:  2014-09-30

6.  A novel t(3;12)(q21;p13) translocation in a patient with accelerated chronic myeloid leukemia after imatinib and nilotinib therapy.

Authors:  Ayda Bennour; Ikram Tabka; Yosra Ben Youssef; Zahra Kmeira; Abderrahim Khelif; Ali Saad; Halima Sennana
Journal:  Cancer Biol Med       Date:  2013-03       Impact factor: 4.248

7.  Polyploidy in myelofibrosis: analysis by cytogenetic and SNP array indicates association with advancing disease.

Authors:  Nisha R Singh; Christine M Morris; Mary Koleth; Kelly Wong; Christopher M Ward; William S Stevenson
Journal:  Mol Cytogenet       Date:  2013-12-17       Impact factor: 2.009

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.